Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1922471 | Parkinsonism & Related Disorders | 2009 | 6 Pages |
Abstract
Dopamine (DA) supplementation therapy by L-dopa for Parkinson's disease (PD) was established around 1970. The dose of L-dopa can be reduced by the combined administration of inhibitors of peripheral L-amino acid decarboxylase (AADC), catechol O-methyltransferase (COMT), or monoamine oxidase B (MAO B). DA in the striatum may be produced from exogenously administered L-dopa by various AADC-containing cells, such as serotonin neurons. The long-term administration of L-dopa in PD patients may produce L-dopa–induced dyskinesia (LID), which may be due to chronic overstimulation of supersensitive DA D1 receptors. L-dopa may be used in combination with various new strategies such as gene therapy or transplantation in the future.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Toshiharu Nagatsu, Makoto Sawada,